• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • About Us
  • Our Laboratory
  • Contact Us
NPS Discovery
  • Reports
    • NPS Discovery Dashboard
    • Monographs
    • Trend Reports
    • Public Alerts
    • NPS Scope Recommendations
    • Drug Checking
    • Clinical Reports
    • NPS Discovery Toolkits
  • Resources
    • Publications
    • Presentations
    • Helpful Links
    • NPS in the News
  • CFSRE
Home Public Health Alert Flualprazolam: Potent Benzodiazepine Identified Among Death & Impaired Driving Cases in the U.S.

Flualprazolam: Potent Benzodiazepine Identified Among Death & Impaired Driving Cases in the U.S.

December 5, 2019

Flualprazolam has been confirmed in at least 44 biological specimens associated with postmortem (PM) death investigations and driving under the influence of drugs (DUID) investigations in the United States since June 2019. The objective of this public announcement is to notify public health and public safety officials, law enforcement, clinicians, medical examiners and coroners, laboratory personnel, and all other related communities about information surrounding the emergent benzodiazepine flualprazolam — a novel psychoactive substance (NPS).

NPS benzodiazepines, sometimes referred to as designer benzodiazepines, are synthetically manufactured drugs, often associated with unknown biological effects and health risks, a dangerous combination for any recreational drug user. NPS benzodiazepines resemble traditional benzodiazepines, such as diazepam and alprazolam, but differ with the addition of new elements or functional groups. NPS benzodiazepines are often prepared in powder or tablet form and can be mixed with street level drugs, including traditional benzodiazepines and opioids. NPS benzodiazepines are of public health and safety concern due to high potency at low doses producing strong sedation and amnesia. Additional adverse effects include loss of coordination, drowsiness, dizziness, blurred vision, slurred speech, and, in some cases, death.

More Information and Full Report

Tags: designer benzodiazepines, Flualprazolam, NPS benzodiazepines

Reader Interactions

sidebar

Popular Tags

  • Assessment
  • Toxicology
  • Fentanyl
  • Supply
  • Postmortem
  • Adulterant
  • NPS
  • philadelphia
  • Heroin
  • Raw Material
  • overdose
  • Chemistry
  • Forensic
  • Drug
  • Drug Material
  • drugs
  • Toxic
  • opioid
  • Opioids
  • Public Health

Meet Our Scientists

Alex J. Krotulski, PhD
Associate Director & Program Manager

Mandi L.A. Mohr, MSFS, D-ABFT-FT
Associate Director

Melissa F. Fogarty, MSFS, D-ABFT-FT
Laboratory Manager

Sara E. Walton, BS
Forensic Science Technician

Barry K. Logan, PhD, F-ABFT
Executive Director

Email Us At

npsdiscovery@cfsre.org

Contact Us

  • npsdiscovery@frfoundation.org
  • 215-366-1591

About Us

Newsroom

Follow Us


© 2022 The Center for Forensic Science Research & Education
  • Privacy Policy
  • Terms of Use
  • Sitemap